Stock listing
BOATS:STRO Sutro Biopharma, Inc. Stock
US listing (BOATS) of Sutro Biopharma, Inc. · home listing NASDAQ:STRO
Follow Sutro Biopharma, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:STRO
$8.60 USD +0.10 (+1.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:STRO
- Day range
- $8.39 – $9.08 USDNov 20, 2026
- Volume
- 275,896 sharesNov 20, 2026
- Market cap
- $142.8M USDAt the close on Nov 20, 2026 · price × 16.60M shares outstanding
- 52-week range
- $7.15 – $43.85 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $4.07M USDMedian day 256,225 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:STRO · Home | $8.60 USD | +0.10 (+1.2%) | 275,896 | $8.58 | $9.08 | $8.39 | $8.50 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:STRO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $8.60 | +0.10 | +1.2% | $8.58 | $9.08 | $8.39 | 275,896 | |
| $8.50 | -0.42 | -4.7% | $8.85 | $9.06 | $8.35 | 307,217 | |
| $8.92 | -0.40 | -4.3% | $9.36 | $9.57 | $8.65 | 210,457 | |
| $9.32 | -0.50 | -5.1% | $9.54 | $9.64 | $8.33 | 260,092 | |
| $9.82 | +0.23 | +2.4% | $10.09 | $10.29 | $9.08 | 333,244 | |
| $9.59 | -0.67 | -6.5% | $10.01 | $10.12 | $9.20 | 657,285 | |
| $10.26 | +0.09 | +0.9% | $10.35 | $10.36 | $9.94 | 138,934 | |
| $10.17 | -0.44 | -4.1% | $10.40 | $10.77 | $9.94 | 217,227 | |
| $10.61 | +0.99 | +10.3% | $9.85 | $10.77 | $9.317 | 268,510 | |
| $9.62 | +0.42 | +4.6% | $9.58 | $9.73 | $9.215 | 182,655 | |
| $9.20 | -0.74 | -7.4% | $9.93 | $9.93 | $8.90 | 771,768 | |
| $9.94 | +0.43 | +4.5% | $9.83 | $10.25 | $9.36 | 158,744 | |
| $9.51 | +0.40 | +4.4% | $9.20 | $9.836 | $9.025 | 127,756 | |
| $9.11 | +0.01 | +0.1% | $9.10 | $9.345 | $8.94 | 147,922 | |
| $9.10 | -0.04 | -0.4% | $9.04 | $9.40 | $8.802 | 122,290 | |
| $9.14 | -0.15 | -1.6% | $9.36 | $9.755 | $9.08 | 260,214 | |
| $9.29 | +0.42 | +4.7% | $8.69 | $9.305 | $8.46 | 353,521 | |
| $8.87 | -0.015 | -0.2% | $8.87 | $9.14 | $8.44 | 453,236 | |
| $8.885 | -0.445 | -4.8% | $9.32 | $9.428 | $8.11 | 694,461 | |
| $9.33 | -0.96 | -9.3% | $10.22 | $10.29 | $9.16 | 430,837 | |
| $10.29 | -0.50 | -4.6% | $10.69 | $10.93 | $10.00 | 293,292 | |
| $10.79 | -0.75 | -6.5% | $11.62 | $11.80 | $10.75 | 439,854 | |
| $11.54 | +0.285 | +2.5% | $11.25 | $11.70 | $11.11 | 273,807 | |
| $11.26 | +0.315 | +2.9% | $11.01 | $11.46 | $10.75 | 345,147 | |
| $10.94 | -0.52 | -4.5% | $11.47 | $11.47 | $10.59 | 363,464 | |
| $11.46 | +0.94 | +8.9% | $10.54 | $11.65 | $10.51 | 418,381 | |
| $10.52 | -0.49 | -4.5% | $10.99 | $11.31 | $10.36 | 489,824 | |
| $11.01 | -2.27 | -17.1% | $13.11 | $13.19 | $10.84 | 406,676 | |
| $13.28 | -0.99 | -6.9% | $14.08 | $14.21 | $12.83 | 298,744 | |
| $14.27 | -1.05 | -6.9% | $15.31 | $15.42 | $14.05 | 256,225 | |
| $15.32 | +0.66 | +4.5% | $14.46 | $16.21 | $14.40 | 499,983 | |
| $14.66 | +0.21 | +1.5% | $14.24 | $15.78 | $14.01 | 232,534 | |
| $14.45 | -0.68 | -4.5% | $15.14 | $15.47 | $14.37 | 162,793 | |
| $15.13 | -0.22 | -1.4% | $15.46 | $15.46 | $14.27 | 160,397 | |
| $15.35 | -0.62 | -3.9% | $16.15 | $16.15 | $14.59 | 372,135 | |
| $15.97 | -0.14 | -0.9% | $16.07 | $16.32 | $15.62 | 196,925 | |
| $16.11 | +0.01 | +0.1% | $16.22 | $16.66 | $15.85 | 133,973 | |
| $16.10 | +0.07 | +0.4% | $16.05 | $16.27 | $15.74 | 202,398 | |
| $16.03 | +0.05 | +0.3% | $15.89 | $16.24 | $15.20 | 165,702 | |
| $15.98 | +0.27 | +1.7% | $15.61 | $16.19 | $14.95 | 292,052 | |
| $15.71 | -0.02 | -0.1% | $15.68 | $16.00 | $15.15 | 252,896 | |
| $15.73 | -0.40 | -2.5% | $16.09 | $16.17 | $15.56 | 294,016 | |
| $16.13 | -0.22 | -1.3% | $16.43 | $16.55 | $16.00 | 246,239 | |
| $16.35 | +1.01 | +6.6% | $14.99 | $16.52 | $14.99 | 320,338 | |
| $15.34 | -0.14 | -0.9% | $15.58 | $15.58 | $14.81 | 651,375 | |
| $15.48 | -0.12 | -0.8% | $15.94 | $16.13 | $15.25 | 348,384 | |
| $15.60 | -0.96 | -5.8% | $16.66 | $16.80 | $15.17 | 273,298 | |
| $16.56 | -0.35 | -2.1% | $16.82 | $16.82 | $15.43 | 1,294,196 | |
| $16.91 | +0.05 | +0.3% | $17.09 | $17.41 | $16.53 | 251,661 | |
| $16.86 | -0.97 | -5.4% | $18.07 | $18.27 | $16.48 | 942,335 | |
| $17.83 | -0.525 | -2.9% | $18.01 | $18.21 | $17.58 | 169,204 | |
| $18.36 | -0.745 | -3.9% | $19.01 | $19.46 | $18.24 | 145,605 | |
| $19.10 | -0.97 | -4.8% | $19.61 | $19.76 | $19.04 | 153,539 | |
| $20.07 | -0.47 | -2.3% | $20.30 | $20.43 | $19.86 | 124,764 | |
| $20.54 | +0.07 | +0.3% | $20.52 | $20.78 | $19.92 | 158,118 | |
| $20.47 | -0.35 | -1.7% | $20.82 | $21.28 | $19.84 | 134,543 | |
| $20.82 | +0.58 | +2.9% | $19.97 | $21.04 | $19.89 | 129,483 | |
| $20.24 | -0.21 | -1.0% | $20.46 | $20.89 | $19.46 | 169,297 | |
| $20.45 | -0.86 | -4.0% | $21.31 | $21.56 | $20.28 | 143,817 | |
| $21.31 | -0.12 | -0.6% | $21.42 | $21.68 | $21.04 | 92,167 | |
| $21.43 | -0.01 | 0.0% | $21.25 | $21.83 | $20.97 | 214,931 | |
| $21.44 | +0.95 | +4.6% | $20.75 | $21.82 | $20.75 | 108,233 | |
| $20.49 | -0.55 | -2.6% | $21.49 | $21.51 | $19.55 | 275,915 | |
| $21.04 | -0.12 | -0.6% | $21.39 | $21.86 | $20.84 | 194,683 | |
| $21.16 | -0.75 | -3.4% | $21.50 | $22.14 | $20.45 | 154,667 |
Splits
1 split · NASDAQ:STRO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- BOATS:STRO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 33 slides
Latest news
Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
Nov 12, 2026
Closed $9.82 (+2.4%) on Nov 13, 2026
Sutro Biopharma to Participate in Upcoming Investor Conferences
Nov 4, 2026
Closed $9.94 (+4.5%) on Nov 4, 2026
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
Oct 21, 2026
Closed $10.79 (-6.5%) on Oct 21, 2026
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
Oct 12, 2026
Closed $13.28 (-6.9%) on Oct 12, 2026
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Sep 29, 2026
Closed $16.10 (+0.4%) on Sep 29, 2026
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
Aug 12, 2026
Closed $21.30 (-14.9%) on Aug 12, 2026
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
May 14, 2026
Closed $38.97 (+1.4%) on May 15, 2026
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
Apr 19, 2026
Closed $34.58 (+9.6%) on Apr 20, 2026
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
Mar 23, 2026
Closed $21.33 (+3.1%) on Mar 23, 2026
Sutro Biopharma Announces Participation at the 16th World ADC London Summit
Feb 23, 2026
Closed $18.40 (-0.1%) on Feb 23, 2026
Sutro Biopharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 114 in all · newest Nov 12, 2026 · oldest 2019
- Decks
- 67 decks · latest November 2026
Where Sutro Biopharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:STRO · Home listing | NASDAQ | United States | USD |
| gettex:S090 | gettex | Germany | EUR |
| Lang & Schwarz:A41VMF | Lang & Schwarz | Germany | EUR |
| Tradegate:S090 | Tradegate | Germany | EUR |
| LS Exchange:A41VMF | LS Exchange | Germany | EUR |
| BOATS:STRO · This page | BOATS | United States | USD |
| Frankfurt:S090 | Frankfurt | Germany | EUR |
| Dusseldorf:S090 | Dusseldorf | Germany | EUR |
| Munich:S090 | Munich | Germany | EUR |
Valuation
EV/sales 5.8× against a median of 16.0×: 3rd lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $259.6M USD
- P/E
- Loss
- EV/sales
- 5.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 28.3%
- Operating margin
- −265.0%
- Net margin
- −344.2%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.14
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Sutro Biopharma, Inc. · NASDAQ:STRO | US$142.8M | US$259.6M | n/a | 5.8× | n/a | n/a | −344.2% | n/a | 1.14 |
| Veraxa Biotech AG · NASDAQ:VRXA | US$147.1M | US$145.1M | n/a | 5,202× | n/a | n/a | n/a | n/a | 1.11 |
| ProQR Therapeutics N.V. · NASDAQ:PRQR | US$146.8M | US$49.71M | n/a | 2.2× | n/a | 2.0× | −210.7% | 0.2× | 1.73 |
| ALX Oncology Holdings Inc. · NASDAQ:ALXO | US$146.6M | US$9.57M | n/a | n/a | n/a | 1.2× | n/a | 0.1× | 0.68 |
| Bicycle Therapeutics PLC · NASDAQ:BCYC | US$146.1M | −US$323.8M | n/a | −3.9× | n/a | 0.3× | −169.8% | 0.0× | 1.59 |
| BridgeBio Oncology Therapeutics, Inc. · NASDAQ:BBOT | US$145.3M | −US$46.23M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.49 |
| TYK Medicines, Inc. Class H · HKEX:2410 | US$144.9M | US$137.0M | n/a | n/a | n/a | 3.7× | n/a | 0.6× | n/a |
| VISEN Pharmaceuticals · HKEX:2561 | US$140.7M | US$91.29M | n/a | 29.8× | n/a | 1.4× | n/a | 0.3× | n/a |
| Protara Therapeutics, Inc. · NASDAQ:TARA | US$140.4M | US$15.77M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 1.12 |
| Cloudbreak Pharma, Inc. · HKEX:2592 | US$140.4M | US$82.03M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Scancell Holdings PLC · LSE:SCLP | US$140.3M | US$155.7M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Median of the others | US$145.1M | US$65.87M | 16.0× | 1.3× | −190.2% | 0.1× | 1.31 |
Forecasts
10 strong buy · 3 buy · 1 sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 50.42 USD · Analysts' mean
- EPS, year to Dec 2026
- -6.22 · 1 analyst
- Revenue, year to Dec 2026
- 51.15M · 12 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jane Chung | Chief Executive Officer & Member, Board of Directors |
| Greg Chow | Chief Financial Officer |
| Lucas Donigian | Senior Vice President, Business Development |
| Hans-Peter Gerber | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Connie Matsui | Chair, Board of Directors |
| Daniel H. Petree | Member, Board of Directors |
| Heidi Hunter | Member, Board of Directors |
| James Panek | Member, Board of Directors |
| Jane Chung | Chief Executive Officer & Member, Board of Directors |
| Jon Wigginton | Member, Board of Directors |
| Joseph M. Lobacki | Member, Board of Directors |
| Michael Dybbs | Member, Board of Directors |
| Sukhi Jagpal | Member, Board of Directors |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | +2.4% |
| Q2 2026 | Aug 12, 2026 · Before open | −14.9% |
| Q1 2026 | May 14, 2026 · After close | +1.4% |
| Q4 2025 | Mar 12, 2026 | −6.0% |
| Q3 2025 | Nov 6, 2025 · After close | −13.4% |
| Q2 2025 | Aug 7, 2025 · After close | +0.3% |
| Q1 2025 | May 8, 2025 · After close | −9.1% |
| Q4 2024 | Mar 24, 2025 · Before open | +0.4% |
| Q3 2024 | Nov 13, 2024 · After close | −12.9% |
| Q2 2024 | Aug 13, 2024 · After close | +11.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · After close | +2.6% |
| Q4 2023 | Mar 25, 2024 · After close | +27.8% |
| Q3 2023 | Nov 13, 2023 · After close | +14.5% |
| Q2 2023 | Aug 10, 2023 · After close | −1.8% |
| Q1 2023 | May 15, 2023 · Before open | +4.3% |
| Q4 2022 | Mar 30, 2023 · After close | +3.1% |
| Q3 2022 | Nov 8, 2022 · After close | +2.7% |
| Q2 2022 | Aug 8, 2022 · After close | +6.6% |
| Q1 2022 | May 9, 2022 · After close | +6.0% |
| Q4 2021 | Feb 28, 2022 · After close | −2.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 33 slides | November 2026 |
| Investor Presentation (November 2026) | Investor deck | 32 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 33 slides | October 2026 |
| Investor Presentation (August 2026) | Investor deck | 29 slides | August 2026 |
| Investor Presentation (February 2026) | Investor deck | 27 slides | Feb 10, 2026 |
| Investor Day (November 2025) | Investor day | 57 slides | Nov 12, 2025 |
| Investor Presentation (November 2025) | Investor deck | 29 slides | November 2025 |
| Investor Presentation (November 2025) | Investor deck | 32 slides | November 2025 |
| Investor Presentation (October 2025) | Investor deck | 29 slides | October 2025 |
| Investor Presentation (September 2025) | Investor deck | 29 slides | September 2025 |
Show 50 decks
This page holds 50 of 67 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: about US$110M · US$13.98 a share · Leerink Partners +2 Dealers: Leerink Partners (co-lead), TD Cowen (co-lead), LifeSci Capital (co-lead) Buyers: BVF Partners L.P.; Samsara BioCapital; Coastlands Capital; Eventide Asset Management; Perceptive Advisors; RA Capital Management; ADAR1 Capital Management; Affinity Asset Advisors; Acuta Capital Partners Use of proceeds: General corporate purposes, including research, clinical and process development and manufacturing of product candidates, and working capital | Feb 10, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$15.00 a share on Sep 26, 2018.
- Price
- US$15.00 a share
- Shares offered
- 5,667,000 shares of common stock
- Offering size
- US$85 million
- Underwriters' option
- Up to 850,050 more shares
- Underwriters
- Cowen, Piper Jaffray, JMP Securities, Wedbush PacGrow · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 1, 2018 |
| Filed publicly | Aug 29, 2018 |
| Amended once | Sep 17, 2018 |
| Shares registered with an exchange | Sep 18, 2018 |
| Declared effective by the SEC | Sep 26, 2018 |
| Final prospectus, with the price | Sep 27, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 27, 2018 |
| EFFECT · Notice that a registration is effective | Sep 26, 2018 |
| S-1MEF · Registration of more shares for the same offering | Sep 26, 2018 |
| CORRESP · Letter to the SEC | Sep 24, 2018 |
| CORRESP · Letter to the SEC | Sep 24, 2018 |
| CERT · Exchange's certificate of listing | Sep 21, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 18, 2018 |
| CORRESP · Letter to the SEC | Sep 17, 2018 |
| S-1/A · Registration statement, amended | Sep 17, 2018 |
| UPLOAD · Letter from the SEC | Sep 11, 2018 |
All 21 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Sep 10, 2018 |
| CORRESP · Letter to the SEC | Aug 29, 2018 |
| S-1 · Registration statement | Aug 29, 2018 |
| UPLOAD · Letter from the SEC | Aug 24, 2018 |
| DRSLTR · Letter to the SEC with a draft | Aug 20, 2018 |
| DRSLTR · Letter to the SEC with a draft | Aug 8, 2018 |
| UPLOAD · Letter from the SEC | Jul 30, 2018 |
| DRSLTR · Letter to the SEC with a draft | Jul 10, 2018 |
| DRS/A · Draft registration statement, amended | Jul 10, 2018 |
| UPLOAD · Letter from the SEC | Jun 29, 2018 |
| DRS · Draft registration statement | Jun 1, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 27, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102.5M | 62.0M | 153.7M | 67.8M | 61.9M | 42.7M | 42.7M | 38.4M | 51.7M | 59.7M |
| Cost of revenue | 7.32M | 7.22M | 6.82M | 8.29M | 9.77M | 77.0M | 65.6M | 54.3M | 51.9M | 43.5M |
| Gross profit | 95.2M | 54.8M | 146.9M | 59.5M | 52.1M | -34.2M | 42.7M | -15.8M | -156.0K | 16.2M |
| Research and development | 166.4M | 252.0M | 180.4M | 137.2M | 104.4M | 77.0M | 65.6M | 54.3M | 54.6M | 43.5M |
| Selling, general and administrative | 41.0M | 48.5M | 62.6M | 59.5M | 56.0M | 36.8M | 32.6M | 21.4M | 16.4M | 14.8M |
| Operating income | -158.4M | -238.5M | -89.3M | -128.9M | -98.5M | -71.1M | -55.5M | -37.2M | -19.3M | 1.36M |
| Depreciation and amortization | 7.32M | 7.22M | 6.82M | 5.69M | 4.84M | 4.30M | 4.78M | 4.54M | 4.99M | 5.66M |
| EBITDA | -151.0M | -231.2M | -82.5M | -123.3M | -93.7M | -66.8M | -50.7M | -32.7M | -14.3M | 7.03M |
| Interest expense | 38.2M | 31.1M | 1.30M | 2.40M | 2.60M | 2.30M | 1.10M | 1.62M | 612.0K | 0 |
| Income before tax | -191.2M | -225.1M | -88.6M | -116.7M | -105.5M | -32.0M | -55.7M | -35.3M | -19.7M | 1.70M |
| Income tax | -93.0K | 2.36M | 18.2M | 2.50M | 0 | 103.0K | 0 | 0 | 0 | 87.0K |
| Net income | -191.1M | -227.5M | -106.8M | -119.2M | -105.5M | -32.1M | -119.2M | -35.3M | -19.7M | 1.70M |
| Earnings per share, basic | -22.49 | -29.40 | -1.78 | -2.35 | -2.29 | -0.99 | -2.43 | -6.13 | -43.95 | 0.00 |
| Earnings per share, diluted | -22.49 | -29.40 | -1.78 | -2.35 | -2.29 | -0.99 | -2.43 | -6.13 | -43.95 | 0.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 58.1M | 190.3M | 69.3M | 47.3M | 30.4M | 206.2M | 4.96M | 125.3M | 22.0M | 11.6M |
| Short-term investments | 83.3M | 126.6M | 264.4M | 255.1M | 130.3M | 120.3M | 112.9M | 79.2M | 0 | 35.9M |
| Receivables | 3.98M | 8.62M | 36.1M | 7.12M | 12.5M | 5.56M | 6.30M | 2.49M | 1.62M | 577.0K |
| Inventory | 1 | -11.7M | 1 | 1 | ||||||
| Current assets | 150.9M | 343.3M | 421.5M | 353.2M | 218.5M | 378.2M | 128.6M | 209.9M | 25.6M | 49.7M |
| Property, plant and equipment | 10.6M | 18.2M | 21.9M | 24.6M | 22.6M | 12.9M | 9.63M | 10.9M | 14.0M | 18.7M |
| Total assets | 173.8M | 387.2M | 470.7M | 406.9M | 341.4M | 394.1M | 156.4M | 223.1M | 40.8M | 69.3M |
| Accounts payable | 7.57M | 10.5M | 9.44M | 4.80M | 6.01M | 5.54M | 5.58M | 3.06M | 2.90M | 3.39M |
| Current liabilities | 75.1M | 131.9M | 93.7M | 66.5M | 41.7M | 29.6M | 33.0M | 36.4M | 32.0M | 50.2M |
| Long-term debt | 0 | 3.77M | 15.7M | 24.5M | 8.88M | 10.0M | 1.71M | 1.19M | ||
| Total debt | 15.7M | 23.2M | 4.06M | 16.3M | 25.1M | 24.5M | 8.88M | 14.7M | 16.3M | 1.19M |
| Total liabilities | 306.3M | 342.6M | 321.1M | 189.9M | 88.8M | 62.1M | 58.6M | 91.6M | 47.3M | 160.2M |
| Shareholders' equity | -132.5M | 44.6M | 149.6M | 217.0M | 252.6M | 332.0M | 97.8M | 131.5M | -109.0M | -90.9M |
| Shares outstanding | 8.58M | 8.31M | 61.0M | 57.5M | 46.3M | 45.8M | 23.1M | 22.8M | 465.3K | 23.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -177.2M | -191.5M | -111.6M | 3.55M | -81.7M | -67.8M | -65.0M | 12.7M | -37.1M | -13.2M |
| Capital spending | -1.70M | -3.10M | -4.32M | -7.86M | -15.3M | -7.13M | -3.48M | -1.56M | -3.32M | -4.39M |
| Free cash flow | -178.9M | -194.6M | -115.9M | -4.31M | -97.0M | -74.9M | -68.5M | 11.1M | -40.4M | -17.5M |
| Cash from investing | 45.0M | 218.5M | -3.92M | -35.0M | -97.3M | 604.0K | -51.1M | -80.2M | 32.6M | 9.59M |
| Cash from financing | 44.0K | 94.1M | 137.6M | 48.3M | 3.26M | 269.2M | -4.18M | 170.8M | 14.6M | 177.0K |
| Dividends paid | -463.0K | -314.0K | -297.0K | |||||||
| Share buybacks | -490.0K | -463.0K | -7.00K | -314.0K | -327.0K | 84.4M | 15.1M | 184.0K | ||
| Change in cash | -132.2M | 121.0M | 22.0M | 16.8M | -175.7M | 202.0M | -120.3M | 103.3M | 10.2M | -3.38M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 9, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 30, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 1, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 22, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 21, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 21, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 2, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Apr 1, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 30, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 27, 2026 | Other filings | SEC |
| S-3 · Registration statement | Mar 23, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 23, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 23, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 23, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 18, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 10, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Feb 10, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 29, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 3, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 29, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 30, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 25, 2025 | Current report | SEC |
| 8-K · Current report | Jun 10, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 2, 2025 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | May 30, 2025 | Offer document | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 15, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 14, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 14, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 8, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 4, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jul 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2024 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 17, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 12, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Apr 5, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Apr 2, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Apr 2, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 2, 2024 | Material contract | SEC |
| 10-K · Annual report | Mar 25, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2024 | Results | SEC |
| 4/A · Change in ownership, amended | Mar 22, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 22, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
This page holds 200 of 628 filings. Open Filings
Cap table
Built by 6ix from Sutro Biopharma, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 16,601,411
- Fully diluted
- 16,601,411
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 16,601,411 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 16,601,411 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Shalini Sharp Other companies: Iambic Therapeutics, Inc. (Board Member · Since at least Nov 5, 2026); BeOne Medicines Ltd. Class A (Director · Since at least Jun 11, 2026); Septerna, Inc. (Director · Since at least Oct 24, 2024); Organon & Co. (Director · Since at least May 14, 2021); Neurocrine Biosciences, Inc. (Director · Since at least Feb 1, 2020); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Precision BioSciences, Inc. (Director · Mar 27, 2019 – May 10, 2021 · Past); Ultragenyx Pharmaceutical Inc. (EVP, Finance · Jan 30, 2014 – Oct 14, 2020 · Past); Agenus Inc. (Director · Oct 1, 2006 – Mar 2, 2018 · Past) | Director · Nov 8, 2018 – Jun 6, 2022 · Past |
| John G. Freund Other companies: SI-BONE, Inc. (Director · Since at least Oct 16, 2018); Collegium Pharmaceutical, Inc. (Director · Since at least May 6, 2015); Protara Therapeutics, Inc. (Director · Oct 21, 2014 – Nov 8, 2019 · Past); Concert Pharmaceuticals Inc (Director · Feb 12, 2014 – Feb 20, 2014 · Past); Tetraphase Pharmaceuticals Inc (Director · Mar 19, 2013 – Dec 10, 2019 · Past); Sirtris Pharmaceuticals Inc (Director · May 22, 2007 – May 29, 2007 · Past); Hansen Medical Inc (Director · Nov 15, 2006 – Jun 17, 2009 · Past); XenoPort Inc (Director · May 2, 2006 – Jul 5, 2016 · Past) | Director · Sep 26, 2018 – Jun 6, 2024 · Past |
| Daniel Janney Other companies: Krystal Biotech, Inc. (Director · Since at least Sep 19, 2017); Allakos Inc (Director · Jul 18, 2018 – May 25, 2023 · Past); Viveve Medical, Inc. (Director · Aug 22, 2016 – Dec 31, 2018 · Past); Evofem Biosciences, Inc. (Director · Nov 19, 2014 – Jun 16, 2015 · Past); Esperion Therapeutics, Inc. (Director · Jun 25, 2013 – May 27, 2021 · Past) | Director · Sep 26, 2018 – Jun 17, 2019 · Past |
| Michael Jay Ross Other companies: Xilio Therapeutics, Inc. (Director · Oct 21, 2021 – Jun 15, 2022 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Deciphera Pharmaceuticals LLC (Director · Sep 27, 2017 – Jun 11, 2019 · Past); Astria Therapeutics Inc (Director · Jun 24, 2015 – Jun 7, 2018 · Past); IVERIC bio Inc (Director · Sep 24, 2013 – May 23, 2018 · Past) | Director · Sep 26, 2018 – Sep 27, 2018 · Past |
| V Bryan Lawlis Other companies: Spyre Therapeutics, Inc. (Director · Jul 13, 2018 – Jun 7, 2022 · Past); Coherus Oncology, Inc. (Director · Nov 6, 2014 – Jan 11, 2021 · Past); Humanigen Inc (Director · Aug 7, 2013 – Jun 18, 2014 · Past); BioMarin Pharmaceutical Inc. (Director · May 8, 2012 – May 23, 2023 · Past); Geron Corporation (Director · Mar 13, 2012 – May 21, 2025 · Past) | Director · Sep 26, 2018 – Sep 26, 2018 · Past |
| Michael Dybbs Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Kalaris Therapeutics, Inc. (Director · Since at least Mar 18, 2025); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Dimension Therapeutics (Director · Oct 21, 2015 – Nov 7, 2017 · Past) | Member, Board of Directors · Since at least Sep 26, 2018 |
| Jon Marc Wigginton Other companies: Checkmate Pharmaceuticals Inc (Director · Jan 30, 2022 – May 31, 2022 · Past); Cullinan Therapeutics, Inc. (Chief Medical Officer · Jan 7, 2021 – Jan 7, 2021 · Past); MacroGenics, Inc. (Sr VP, Clinical Dev. & CMO · Oct 9, 2013 – Feb 20, 2020 · Past) | Director · Since at least Nov 30, 2020 |
| Joseph M. Lobacki Other companies: Verastem, Inc. (Executive VP & CCO · Jan 3, 2018 – Jan 3, 2019 · Past); Medivation Inc (Chief Commercial Officer · Dec 8, 2014 – Jan 4, 2016 · Past); Celator Pharmaceuticals Inc (Director · Dec 18, 2013 – Jul 12, 2016 · Past) | Member, Board of Directors · Since at least Sep 26, 2018 |
| Anne Borgman Other companies: Curis, Inc. (Director · Since at least Oct 12, 2022); NextCure, Inc. (Director · Since at least Oct 1, 2021) | CHIEF MEDICAL OFFICER · Feb 28, 2023 – May 1, 2025 · Past |
| Arturo Molina Other companies: Protagonist Therapeutics, Inc. (Chief Medical Officer · Since at least Nov 7, 2022); Forma Therapeutics Holdings Inc (Director · Jan 12, 2022 – Oct 14, 2022 · Past) | Chief Medical Officer · Sep 26, 2018 – Mar 4, 2022 · Past |
All 32 people
| Person | Seat |
|---|---|
| Connie Matsui Other companies: Artelo Biosciences, Inc. (Chair · Since at least Jun 21, 2019); Halozyme Therapeutics, Inc. (Director · May 15, 2007 – Nov 29, 2024 · Past) | Director · Since at least Jun 24, 2019 |
| Daniel H. Petree Other companies: Apollo Endosurgery Inc (Director · Nov 10, 2008 – Dec 29, 2016 · Past); Cypress Bioscience Inc (Director · Jan 2, 2006 – Jan 4, 2010 · Past) | Member, Board of Directors · Since at least Sep 26, 2018 |
| Sukhi Jagpal Other companies: Sierra Oncology Inc (Chief Financial Officer · Jul 15, 2015 – Jul 1, 2022 · Past); Novelion Therapeutics Inc (Chief Financial Officer · Jul 20, 2012 – Jul 15, 2013 · Past) | Member, Board of Directors · Since at least Aug 8, 2024 |
| William J Newell Other companies: Social Capital Suvretta Holdings Corp IV (Director · Sep 7, 2022 – Sep 7, 2022 · Past); Vaxcyte, Inc. (Director · Jun 11, 2020 – Dec 9, 2020 · Past) | CEO, Director · Sep 26, 2018 – Mar 5, 2025 · Past |
| Edward C Albini Other companies: Paratek Pharmaceuticals Inc (V.P., Chief Financial Officer · May 9, 2006 – May 9, 2008 · Past) | CFO AND SECRETARY · Sep 26, 2018 – May 15, 2025 · Past |
| Gregory K Chow Other companies: Aptose Biosciences Inc (Executive VP & CFO · Dec 21, 2018 – Jan 4, 2021 · Past) | CFO · Since at least Jun 2, 2025 |
| Jane Chung Other companies: Viracta Therapeutics Inc (Director · Aug 10, 2022 – Jun 20, 2024 · Past) | Chief Executive Officer & Member, Board of Directors · Since at least Aug 9, 2021 |
| Trevor Hallam Other companies: Palatin Technologies, Inc. (Exec VP - Research & Dev · Oct 6, 2006 – Jul 21, 2010 · Past) | Pres. Rsrch & Cf. Sctific Ofcr · Sep 26, 2018 – Apr 14, 2023 · Past |
| Anik Shabbir | Chief Technical Ops. Officer · Sep 26, 2018 – Mar 3, 2023 · Past |
| Barbara Leyman | Chief Business Officer · Since at least Jul 8, 2024 |
| Brunilda Shtylla | Chief Business Officer · Mar 1, 2023 – Aug 28, 2023 · Past |
| David Pauling | Chief Admin. Ofcr. & GC · Since at least Apr 4, 2025 |
| Greg Chow | Chief Financial Officer · Since at least Jun 2, 2025 |
| Hans-Peter Gerber | Chief Scientific Officer · Since at least Sep 18, 2023 |
| Heidi Hunter | Member, Board of Directors · Since at least Nov 19, 2021 |
| James Panek | Member, Board of Directors · Since at least Jan 7, 2020 |
| Jon Wigginton | Member, Board of Directors · Since at least Nov 4, 2026 |
| Linda A Fitzpatrick | CHIEF PEOPLE & COMM. OFFICER · Sep 26, 2018 – May 1, 2025 · Past |
| Lucas Donigian | Senior Vice President, Business Development · Since Sep 28, 2026 |
| Nicki Vasquez | CHIEF PORT. STRAT & ALNCE OFCR · Aug 9, 2021 – Jan 29, 2024 · Past |
| Stephen Worsley | Chief Business Officer · Sep 26, 2018 – Jan 29, 2019 · Past |
| Venkatesh Srinivasan | CHIEF TECH OP OFFICER · May 1, 2023 – May 1, 2025 · Past |
Log in to ask 6ix AI your own questions about Sutro Biopharma, Inc.